Skip Navigation


Annals of Oncology Advance Access originally published online on February 25, 2008
Annals of Oncology 2008 19(5):958-963; doi:10.1093/annonc/mdn022
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/5/958    most recent
mdn022v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mercadal, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mercadal, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

hematologic malignancies

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

S. Mercadal1, J. Briones2, B. Xicoy3, C. Pedro4, L. Escoda5, C. Estany6, M. Camós1, L. Colomo1, Í. Espinosa2, S. Martínez5, J.M. Ribera3, R. Martino2, G. Gutiérrez-García1, E. Montserrat1, A. López-Guillermo1,* and On behalf of the Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)

1 Departments of Hematology and Pathology, Hospital Clínic
2 Hospital de Sant Pau, Barcelona
3 Hospital Germans Trias I Pujol, Badalona
4 Hospital del Mar, Barcelona
5 Hospital Joan XXIII, Tarragona
6 Hospital Mútua de Terrassa, Terrassa, Spain

* Correspondence to: Dr A. López-Guillermo, Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Tel: +34-932275575; Fax: +34-932275484; E-mail: alopezg{at}clinic.ub.es

Aim: To analyze toxicity, response and outcome of a phase II trial with intensive chemotherapy plus autologous stem-cell transplantation (ASCT) for young patients with peripheral T-cell lymphoma (PTCL).

Patients and methods: Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with PTCL received three courses of high-dose cyclophosphamide 2000 mg/m2/day, adriamycin 90 mg/m2/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone. Responders were submitted to ASCT.

Results: Sixty-eight percent of patients received the planned treatment. After chemotherapy, 20 patients reached complete response (CR), 4 partial response and 17 failed. ASCT was carried out in 17 of 24 candidates due to lack of mobilization (three cases), toxicity (two), early relapse and patient decision (one each). CR rate after treatment was 51%. With a median follow-up of 3.2 years, 5 of 21 CR patients relapsed and 2 died in CR due to secondary neoplasms. Four-year progression-free survival was 30%. Twenty-two patients have died, with a 4-year overall survival of 39%. International Prognostic Index was the main variable predicting survival. No differences were seen among the 24 candidates according to whether or not they underwent ASCT.

Conclusion: This intensive regimen resulted in moderate CR rate, with manageable toxicity in PTCL. The contribution of ASCT in preventing relapse is debatable. Novel strategies to increase CR warrant investigation.

Key words: autologous stem-cell transplantation, peripheral T-cell lymphoma, prognosis

Received for publication January 7, 2008. Accepted for publication January 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.